Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net income (loss)	$ 3,554	$ (161,278)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	46,780	7,685
Non-cash interest	1,408	1,681
Amortization of deferred financing costs	74	895
Losses from investments in investees	4,333	2,565
Equity-based compensation – employees and non-employees	26,105	14,090
Revenue from receipt of equity	0	(120)
Realized gain on equity securities	(2,494)	(216)
Loss on conversion of 3.00% convertible senior notes	0	291
Change in fair value of derivative instruments	188	66,344
Change in fair value of contingent consideration	12,511	4,836
Deferred income tax benefit	(8,999)	0
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net	(18,388)	(4,186)
Inventory, net	(1,763)	(2,547)
Other current assets and prepaid expenses	(14,309)	1,142
Other assets	732	(512)
Accounts payable	(13,205)	7,101
Foreign currency measurement	(405)	300
Deferred revenue	(35,938)	263,926
Accrued expenses and other liabilities	33,452	2,741
Net cash provided by operating activities	33,636	204,738
Cash flows from investing activities:
Investments in investees	(5,921)	(2,345)
Acquisition of businesses, net of cash	0	(94,674)
Purchase of marketable securities	(15,630)	0
Proceeds from the sale of property, plant and equipment	708	0
Capital expenditures	(12,866)	(1,439)
Net cash used in investing activities	(33,709)	(98,458)
Cash flows from financing activities:
Proceeds from the exercise of Common Stock options and warrants	1,912	17,366
Cash from non-controlling interest	0	100
Borrowings on lines of credit	9,496	11,038
Repayments of lines of credit	(49,341)	(10,022)
Net cash (used in) provided by financing activities	(37,933)	18,482
Effect of exchange rate changes on cash and cash equivalents	423	(452)
Net (decrease) increase in cash and cash equivalents	(37,583)	124,310
Cash and cash equivalents at beginning of period	193,598	96,907
Cash and cash equivalents at end of period	156,015	221,217
SUPPLEMENTAL INFORMATION:
Interest paid	900	1,724
Income taxes paid, net	7,172	757
Non-cash financing:
Common Stock options and warrants, surrendered in net exercise	325	14,239
2033 Senior Notes
Non-cash financing:
Shares issued upon conversion, amount	0	92,172
EirGen Pharma Limited
Issuance of capital stock to acquire or contingent consideration settlement:
Capital stock issued	0	33,569
OPKO Health Europe
Issuance of capital stock to acquire or contingent consideration settlement:
Capital stock issued	$ 313	$ 1,813